Bal Pharma Limited (BOM:524824)

Market Cap	1.05B -24.9%
Revenue (ttm)	3.09B -2.0%
Net Income	81.23M +12.0%
EPS	4.82 -1.8%
Shares Out	15.92M
PE Ratio	13.67
Forward PE	n/a
Dividend	1.20 (1.79%)
Ex-Dividend Date	Sep 18, 2025

Volume	38,526
Average Volume	1,411
Open	66.93
Previous Close	66.93
Day's Range	65.25 - 67.15
52-Week Range	64.00 - 128.86
Beta	0.17
RSI	39.40
Earnings Date	May 29, 2026

About Bal Pharma

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic p...

• Industry: Pharmaceutical Preparations
• Founded: 1987
• Employees: 986
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524824

Financial Performance

In fiscal year 2025, Bal Pharma's revenue was 3.03 billion, a decrease of -10.65% compared to the previous year's 3.39 billion. Earnings were 72.15 million, a decrease of -2.39%.